IP Library Granted Patent US 8,541,198
Granted Patent B2
US 8,541,198 · App. 13/023,201 · Granted Sep 24, 2013

Method for determination and quantification of radiation or genotoxin exposure

Inventor: Alan D. D'Andrea (Winchester, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,198
App. No.
13/023,201
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents.

Claims (10)

1. A method of detecting exposure to a genotoxic agent, comprising:

(a) identifying a subject who is at risk of being exposed to said genotoxic agent;

(b) collecting a sample from said subject;

(c) detecting the number of FANCD2-containing foci in said sample;

(d) detecting the number of FANCD2-containing foci in a control sample; and

(e) comparing the number of FANCD2-containing foci detected in (c) with the number of FANCD2-containing foci detected in (d),

wherein if the number of FANCD2-containing foci detected in (c) exceeds the number of FANCD2-containing foci detected in (d), said exposure to said genotoxic agent is detected.

2. The method of claim 1 , further comprising contacting said sample with a ligand which binds to human FANCD2 of SEQ ID NO: 1, wherein said ligand is associated with a label which provides a detectable signal.

3. The method of claim 2 , wherein said ligand comprises a protein that binds to human FANCD2 of SEQ ID NO: 1 and is fused in frame with a fluorophore.

4. The method of claim 1 , further comprising before step (d), a step of exposing said control sample to said genotoxic agent.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 5, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040807/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2011
From: D'ANDREA, ALAN D.
To: DANA FARBER CANCER INSTITUTE
Reel/Frame 026831/0037 →
Continuity (4)
Continuation 12315368 · Dec 1, 2008
Continuation 11046346 · Jan 28, 2005
Provisional Application 60540380 · Jan 30, 2004
Related Publication 20110312514A1 · Dec 22, 2011